Acomplia (rimonabant) is a new medicine for obese patients (BMI > 30) or overweight patients (BMI > 27) with associated risk factors such as type 2-diabetes or dyslipidaemia. The dose is 20 mg daily, before breakfast.
A year of treatment with Acomplia results in a placebo adjusted weight loss of 4-5 kg. You need to treat 5-7 patients for one year to achieve, that one patient experience a weight loss of at least 10 % of the body weight. Simultaneously the S-HDL increases and the S-triglycerides decrease. In obese patients with type 2-diabetes the HbA1c decreases by approximately 0,7 %.
There are no trials evaluating Acomplia‘s influence on the risk of cardiovascular diseaseand no trials comparing Acomplia and other medicines against obesitylike orlistat (Xenical) or sibutamin (Reductil). Acomplia has not been trialled on children or younger people under 18 years.
The most important adverse effects are nausea, depression/mood alterations, irritability, anxiety, insomnia and dizziness. The summary of product characteristics (SPC) contains cautions about the use of Acomplia in patients with pronounced depression or inpatients that currently use anti-depressants.
Acomplia costs roughly the same as Xenical and Reductil. The price is 25,86 dkr/day or 9.400 dkr/year. The reimbursement status of Acomplia is not yet decided.
Acomplia was marketed 14 August 2006.
Institute for Rational Pharmacotherapy, 25 August 2006